Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster lunch

1533 - Loss of CDKL2 expression correlates with differentiation, stage, and poor prognosis of gastric cancer (43P)

Date

18 Nov 2017

Session

Poster lunch

Presenters

Kai-Yuan Lin

Citation

Annals of Oncology (2017) 28 (suppl_10): x7-x15. 10.1093/annonc/mdx653

Authors

K. Lin1, Y. Uen2

Author affiliations

  • 1 Department Of Medical Research, Chi-Mei Medical Center, 710 - Tainan/TW
  • 2 The Superintendent's Office, Chi-Mei Hospital Chiali, 722 - Tainan/TW
More

Resources

Abstract 1533

Background

Gastric cancer (GC) remains a major public health problem throughout the world. In this study, we investigated the involvement of a new member of cyclin-dependent kinases, cyclin-dependent kinase-like 2 (CDKL2) in tumor progression, and in the prognosis of human GC.

Methods

The patient cohort in this study consisted of 151 GC cases, documenting pathologic and clinical factors, as well as clinical outcomes. Immunohistochemistry and immunoblotting were employed to examine the CDKL2 expression in 151 pairs of normal and GC tissues and 5 gastric cells. Based on the expression of CDKL2, two GC cell with low CDKL2 level was chosen for CDKL2 overexpression. The effect of CDKL2 overexpression on the growth of CDKL2-manupulated GC cells was examined.

Results

Downregulation of CDKL2 protein was observed in 83 patients and was significantly correlated with Lauren classification, staging, degree of differentiation, and poor disease-free survival. Univariate Cox regression analysis showed that loss of CDKL2 is a prognostic marker for GC. Furthermore, CDKL2 expression was suppressed in several GC cells. In vitro experiments indicated that CDKL2 overexpression inhibited GC cell growth.

Conclusions

This study suggests that loss of CDKL2 can be a useful marker for predicting the outcome of GC patients.

Clinical trial identification

Not applicable.

Legal entity responsible for the study

The institutional review board at Chi-Mei Medical Center

Funding

Chi-Mei Medical Center

Disclosure

All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings